We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Reliable Diagnostic Test Developed for Scabies

By LabMedica International staff writers
Posted on 22 Nov 2011
A fluoroimmunoassay has been developed to determine the specific antibodies in the blood of patients infested with the human itch mite, Sarcoptes scabiei. More...


Scabies antigen specific immunoglobulin E (IgE) was measured by a dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) and quantified, while a competitive inhibition enzyme-linked immunosorbent assay (ELISA) was also conducted.

Scientists from the Menzies School of Health Research, (Darwin, NT, Australia) collaborated with other institutions, to create recombinant allergens to S. scabiei and house dust mites (HDM). Specific IgE antibodies to a major scabies antigen recombinant Sar s 14.3 (rSar s 14.3) were measured in 140 plasma samples from scabies-infested and control subject groups. The 140 consenting volunteers consisted of six groups: 30 subjects with crusted scabies; 30 subjects with ordinary scabies; 30 previously exposed but currently noninfested subjects; 30 subjects naïve to scabies; 10 naïve subjects with atopic allergy as defined by positive skin prick test to a panel of common aeroallergens; and 10 naïve subjects with known allergy to human dust mites based on clinical history and positive specific IgE.

The mean IgE binding to the recombinant antigen for the crusted scabies group was significantly greater compared to each of the other groups. The ordinary scabies group also had a significantly higher mean value than each noninfested group, and the exposed but noninfested group's mean IgE response was significantly greater than the mean response for the naïve to scabies group. The recombinant antigen DELFIA (Wallac; Turku, Finland) showed excellent diagnostic capability, with 100% sensitivity and 93.75% specificity for distinguishing subjects with current scabies infestation from control, uninfested subjects.

The authors concluded that the results demonstrate sensitive detection of IgE reactivity with genus-specific scabies mite epitopes and differential diagnosis of scabies mite allergy from allergy to HDM. The recombinant antigen specific IgE DELFIA has high diagnostic efficiency, with accuracy superior to other diagnostic methods currently available for scabies. Due to the high sensitivity, specificity, accuracy, predictive values, and area under the ROC curve, the developed DELFIA represents a marked improvement for the clinical diagnosis of scabies and helps direct future development of a specific diagnostic tool for scabies. The study was published on October 21, 2011, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Menzies School of Health Research
Wallac


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Hematology Consumables
Bioblood Devices
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.